Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men
India has successfully reduced Human Immuno-deficiency Virus (HIV) incidence, with a 66% decline since the year 2000 has been seen; however, control among Men having sex with Men (MSM) and transgender women (TGW) remains a critical challenge. Oral Pre-Exposure Prophylaxis (PrEP) may help close a cri...
Gespeichert in:
| Veröffentlicht in: | PloS one 2023-06, Vol.18 (6), p.e0287454 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | e0287454 |
| container_title | PloS one |
| container_volume | 18 |
| creator | Sahay, Seema Bangar, Sampada Chandhiok, Nomita |
| description | India has successfully reduced Human Immuno-deficiency Virus (HIV) incidence, with a 66% decline since the year 2000 has been seen; however, control among Men having sex with Men (MSM) and transgender women (TGW) remains a critical challenge. Oral Pre-Exposure Prophylaxis (PrEP) may help close a critical HIV prevention gap for MSM and TGW in India; however, no studies to date have evaluated the feasibility of oral PrEP among MSM and TGW in India. The proposed study aims at understanding the implementation of the provision of daily oral-Tenofovir (TDF) containing PrEP among MSM and TGW through the clinic and community-based delivery models in Pune, Maharashtra, and Jalandhar, Punjab respectively in India. The study aims at estimating PrEP adherence, facilitators, and barriers to PrEP use, retention, acceptability, and willingness to pay for PrEP. After the screening, eligible participants (n = 600) will receive PrEP medicines and will be monitored quarterly for HIV, STIs, and renal and liver toxicity for 12 months as per the schedule of events. The primary outcomes of interest are PrEP acceptability, PrEP adherence, retention rate, adverse medical events, and sexual behavioural changes with PrEP use and breakthrough infections while on PrEP. The study will assess the feasibility of two service delivery models; however, the data from the two service delivery models will be analyzed independently and will not be compared for feasibility and other outcome indicators. The study has been initiated after obtaining appropriate regulatory approvals. PrEP is efficacious in preventing HIV among high-risk population however there are scarce data on providing PrEP to MSM and TGW. The study will provide critical evidence to programs and policymakers on the implementation of PrEP in a "real world" setting, among MSM and TGW in India including identifying populations that can benefit most from this additional HIV prevention intervention along with acceptable delivery strategies and means of support for adherence. |
| doi_str_mv | 10.1371/journal.pone.0287454 |
| format | Article |
| fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_incontextgauss_ISR_A754385913</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A754385913</galeid><sourcerecordid>A754385913</sourcerecordid><originalsourceid>FETCH-LOGICAL-g993-c9d2c4e13feaa3a2f689d512ca58f2abf2478822c49d03ea2b8fc1609da328c53</originalsourceid><addsrcrecordid>eNqFkEtLAzEUhYMoWKv_wEVWgtCpk2QeybL0oQWhRYvbcpu58ygzSZmkWv-9HXVRV67OvZfvHDiXkFsWDplI2cPW7lsD9XBnDQ5DLtMojs5IjynBg4SH4vxkviRXzm3DMBYySXqkmWBjjfMt-MoaumvtFrWnNqe2hZquJrNAW-OhMpUp6LKdLgcUsua4Oo8tZgNqjcYgg6r-_LYcxVvaoKElvHcehwf6Ufmyu12Tixxqhze_2ier2XQ1fgqeF4_z8eg5KJQSgVYZ1xEykSOAAJ4nUmUx4xpimXPY5DxKpeRHRmWhQOAbmWuWhCoDwaWORZ_c_8QWUOO6Ml0DPPgC9s6t568v61EaR0LGiol_2MXbX_buhC0Ral86W--717lT8AvgPHsO</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men</title><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Sahay, Seema ; Bangar, Sampada ; Chandhiok, Nomita</creator><creatorcontrib>Sahay, Seema ; Bangar, Sampada ; Chandhiok, Nomita</creatorcontrib><description>India has successfully reduced Human Immuno-deficiency Virus (HIV) incidence, with a 66% decline since the year 2000 has been seen; however, control among Men having sex with Men (MSM) and transgender women (TGW) remains a critical challenge. Oral Pre-Exposure Prophylaxis (PrEP) may help close a critical HIV prevention gap for MSM and TGW in India; however, no studies to date have evaluated the feasibility of oral PrEP among MSM and TGW in India. The proposed study aims at understanding the implementation of the provision of daily oral-Tenofovir (TDF) containing PrEP among MSM and TGW through the clinic and community-based delivery models in Pune, Maharashtra, and Jalandhar, Punjab respectively in India. The study aims at estimating PrEP adherence, facilitators, and barriers to PrEP use, retention, acceptability, and willingness to pay for PrEP. After the screening, eligible participants (n = 600) will receive PrEP medicines and will be monitored quarterly for HIV, STIs, and renal and liver toxicity for 12 months as per the schedule of events. The primary outcomes of interest are PrEP acceptability, PrEP adherence, retention rate, adverse medical events, and sexual behavioural changes with PrEP use and breakthrough infections while on PrEP. The study will assess the feasibility of two service delivery models; however, the data from the two service delivery models will be analyzed independently and will not be compared for feasibility and other outcome indicators. The study has been initiated after obtaining appropriate regulatory approvals. PrEP is efficacious in preventing HIV among high-risk population however there are scarce data on providing PrEP to MSM and TGW. The study will provide critical evidence to programs and policymakers on the implementation of PrEP in a "real world" setting, among MSM and TGW in India including identifying populations that can benefit most from this additional HIV prevention intervention along with acceptable delivery strategies and means of support for adherence.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0287454</identifier><language>eng</language><publisher>Public Library of Science</publisher><subject>Analysis ; Dosage and administration ; Drug therapy ; Health aspects ; HIV (Viruses) ; HIV infection ; Medical research ; Medicine, Experimental ; MSM (Men who have sex with men) ; Oral medication ; Prevention ; Sexually transmitted diseases ; Tenofovir ; Transgender people ; Women</subject><ispartof>PloS one, 2023-06, Vol.18 (6), p.e0287454</ispartof><rights>COPYRIGHT 2023 Public Library of Science</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,861,27905,27906</link.rule.ids></links><search><creatorcontrib>Sahay, Seema</creatorcontrib><creatorcontrib>Bangar, Sampada</creatorcontrib><creatorcontrib>Chandhiok, Nomita</creatorcontrib><title>Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men</title><title>PloS one</title><description>India has successfully reduced Human Immuno-deficiency Virus (HIV) incidence, with a 66% decline since the year 2000 has been seen; however, control among Men having sex with Men (MSM) and transgender women (TGW) remains a critical challenge. Oral Pre-Exposure Prophylaxis (PrEP) may help close a critical HIV prevention gap for MSM and TGW in India; however, no studies to date have evaluated the feasibility of oral PrEP among MSM and TGW in India. The proposed study aims at understanding the implementation of the provision of daily oral-Tenofovir (TDF) containing PrEP among MSM and TGW through the clinic and community-based delivery models in Pune, Maharashtra, and Jalandhar, Punjab respectively in India. The study aims at estimating PrEP adherence, facilitators, and barriers to PrEP use, retention, acceptability, and willingness to pay for PrEP. After the screening, eligible participants (n = 600) will receive PrEP medicines and will be monitored quarterly for HIV, STIs, and renal and liver toxicity for 12 months as per the schedule of events. The primary outcomes of interest are PrEP acceptability, PrEP adherence, retention rate, adverse medical events, and sexual behavioural changes with PrEP use and breakthrough infections while on PrEP. The study will assess the feasibility of two service delivery models; however, the data from the two service delivery models will be analyzed independently and will not be compared for feasibility and other outcome indicators. The study has been initiated after obtaining appropriate regulatory approvals. PrEP is efficacious in preventing HIV among high-risk population however there are scarce data on providing PrEP to MSM and TGW. The study will provide critical evidence to programs and policymakers on the implementation of PrEP in a "real world" setting, among MSM and TGW in India including identifying populations that can benefit most from this additional HIV prevention intervention along with acceptable delivery strategies and means of support for adherence.</description><subject>Analysis</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Health aspects</subject><subject>HIV (Viruses)</subject><subject>HIV infection</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>MSM (Men who have sex with men)</subject><subject>Oral medication</subject><subject>Prevention</subject><subject>Sexually transmitted diseases</subject><subject>Tenofovir</subject><subject>Transgender people</subject><subject>Women</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkEtLAzEUhYMoWKv_wEVWgtCpk2QeybL0oQWhRYvbcpu58ygzSZmkWv-9HXVRV67OvZfvHDiXkFsWDplI2cPW7lsD9XBnDQ5DLtMojs5IjynBg4SH4vxkviRXzm3DMBYySXqkmWBjjfMt-MoaumvtFrWnNqe2hZquJrNAW-OhMpUp6LKdLgcUsua4Oo8tZgNqjcYgg6r-_LYcxVvaoKElvHcehwf6Ufmyu12Tixxqhze_2ier2XQ1fgqeF4_z8eg5KJQSgVYZ1xEykSOAAJ4nUmUx4xpimXPY5DxKpeRHRmWhQOAbmWuWhCoDwaWORZ_c_8QWUOO6Ml0DPPgC9s6t568v61EaR0LGiol_2MXbX_buhC0Ral86W--717lT8AvgPHsO</recordid><startdate>20230623</startdate><enddate>20230623</enddate><creator>Sahay, Seema</creator><creator>Bangar, Sampada</creator><creator>Chandhiok, Nomita</creator><general>Public Library of Science</general><scope>IOV</scope><scope>ISR</scope></search><sort><creationdate>20230623</creationdate><title>Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men</title><author>Sahay, Seema ; Bangar, Sampada ; Chandhiok, Nomita</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g993-c9d2c4e13feaa3a2f689d512ca58f2abf2478822c49d03ea2b8fc1609da328c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Analysis</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Health aspects</topic><topic>HIV (Viruses)</topic><topic>HIV infection</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>MSM (Men who have sex with men)</topic><topic>Oral medication</topic><topic>Prevention</topic><topic>Sexually transmitted diseases</topic><topic>Tenofovir</topic><topic>Transgender people</topic><topic>Women</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sahay, Seema</creatorcontrib><creatorcontrib>Bangar, Sampada</creatorcontrib><creatorcontrib>Chandhiok, Nomita</creatorcontrib><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sahay, Seema</au><au>Bangar, Sampada</au><au>Chandhiok, Nomita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men</atitle><jtitle>PloS one</jtitle><date>2023-06-23</date><risdate>2023</risdate><volume>18</volume><issue>6</issue><spage>e0287454</spage><pages>e0287454-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>India has successfully reduced Human Immuno-deficiency Virus (HIV) incidence, with a 66% decline since the year 2000 has been seen; however, control among Men having sex with Men (MSM) and transgender women (TGW) remains a critical challenge. Oral Pre-Exposure Prophylaxis (PrEP) may help close a critical HIV prevention gap for MSM and TGW in India; however, no studies to date have evaluated the feasibility of oral PrEP among MSM and TGW in India. The proposed study aims at understanding the implementation of the provision of daily oral-Tenofovir (TDF) containing PrEP among MSM and TGW through the clinic and community-based delivery models in Pune, Maharashtra, and Jalandhar, Punjab respectively in India. The study aims at estimating PrEP adherence, facilitators, and barriers to PrEP use, retention, acceptability, and willingness to pay for PrEP. After the screening, eligible participants (n = 600) will receive PrEP medicines and will be monitored quarterly for HIV, STIs, and renal and liver toxicity for 12 months as per the schedule of events. The primary outcomes of interest are PrEP acceptability, PrEP adherence, retention rate, adverse medical events, and sexual behavioural changes with PrEP use and breakthrough infections while on PrEP. The study will assess the feasibility of two service delivery models; however, the data from the two service delivery models will be analyzed independently and will not be compared for feasibility and other outcome indicators. The study has been initiated after obtaining appropriate regulatory approvals. PrEP is efficacious in preventing HIV among high-risk population however there are scarce data on providing PrEP to MSM and TGW. The study will provide critical evidence to programs and policymakers on the implementation of PrEP in a "real world" setting, among MSM and TGW in India including identifying populations that can benefit most from this additional HIV prevention intervention along with acceptable delivery strategies and means of support for adherence.</abstract><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0287454</doi><tpages>e0287454</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2023-06, Vol.18 (6), p.e0287454 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_gale_incontextgauss_ISR_A754385913 |
| source | DOAJ Directory of Open Access Journals; Public Library of Science (PLoS); EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Analysis Dosage and administration Drug therapy Health aspects HIV (Viruses) HIV infection Medical research Medicine, Experimental MSM (Men who have sex with men) Oral medication Prevention Sexually transmitted diseases Tenofovir Transgender people Women |
| title | Demonstration project of oral TDF-containing PrEP, administered, once-daily orally to men having sex with men |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T21%3A11%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Demonstration%20project%20of%20oral%20TDF-containing%20PrEP,%20administered,%20once-daily%20orally%20to%20men%20having%20sex%20with%20men&rft.jtitle=PloS%20one&rft.au=Sahay,%20Seema&rft.date=2023-06-23&rft.volume=18&rft.issue=6&rft.spage=e0287454&rft.pages=e0287454-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0287454&rft_dat=%3Cgale%3EA754385913%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A754385913&rfr_iscdi=true |